Elevai Labs, Inc. Common Stock (ELAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Elevai Labs, Inc. Common Stock (ELAB) has a cash flow conversion efficiency ratio of -0.223x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.75 Million) by net assets ($7.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ELAB cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Elevai Labs, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Elevai Labs, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Elevai Labs, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elevai Labs, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Infinity Mining Ltd
AU:IMI
|
-0.021x |
|
iMetal Resources Inc
V:IMR
|
-0.024x |
|
JPMorgan China Growth & Income PLC
LSE:JCGI
|
0.008x |
|
Schroder Real Estate Investment Trust Ltd
LSE:SREI
|
0.029x |
|
Rocky Mountain Liquor Inc
V:RUM
|
-0.051x |
|
Tlou Energy Ltd
AU:TOU
|
-1.918x |
|
Unity Biotechnology Inc
NASDAQ:UBX
|
31.010x |
|
Hansa Trust
LSE:HAN
|
0.007x |
Annual Cash Flow Conversion Efficiency for Elevai Labs, Inc. Common Stock (2020–2025)
The table below shows the annual cash flow conversion efficiency of Elevai Labs, Inc. Common Stock from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Elevai Labs, Inc. Common Stock worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.84 Million | $-5.93 Million | -0.757x | +8.11% |
| 2024-12-31 | $6.66 Million | $-5.49 Million | -0.824x | +30.80% |
| 2023-12-31 | $3.83 Million | $-4.56 Million | -1.191x | +15.06% |
| 2022-12-31 | $1.13 Million | $-1.59 Million | -1.402x | +4.42% |
| 2021-12-31 | $450.63K | $-660.93K | -1.467x | -115.93% |
| 2020-12-31 | $-23.59K | $-217.16K | 9.206x | -- |
About Elevai Labs, Inc. Common Stock
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the med… Read more